News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • 23

    Nov

    20

  • KemPharm Provides Update on Development Pipeline

  • 18

    Nov

    20

  • KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event

  • 29

    Oct

    20

  • KemPharm Reports Third Quarter 2020 Financial Results

  • 26

    Oct

    20

  • KemPharm Postpones Special Meeting of Stockholders, Announces Date for Q3 2020 Results Call

  • 22

    Oct

    20

  • KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting

  • 05

    Oct

    20

  • KemPharm and Corium Expand Relationship with New Consultation Services Agreement

  • 25

    Sep

    20

  • KemPharm Files Preliminary Proxy for Special Meeting of Stockholders

  • 10

    Sep

    20

  • KemPharm’s Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain Therapies

  • 02

    Sep

    20

  • KemPharm to Present at Upcoming September Investor Conferences

  • 14

    Aug

    20

  • KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA

  • 12

    Aug

    20

  • KemPharm Reports Second Quarter 2020 Financial Results

  • 04

    Aug

    20

  • KemPharm to Report Second Quarter 2020 Financial Results